PriceTargets.com logo

HLS Therapeutics - HLTRF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.69
  • Forecasted Upside: 429.92%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.47 As of 03/30/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for HLTRF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New HLS Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HLTRF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HLTRF

Analyst Price Target is $23.69
▲ +429.92% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for HLS Therapeutics in the last 3 months. The average price target is $23.69, with a high forecast of $26.50 and a low forecast of $18.00. The average price target represents a 429.92% upside from the last price of $4.47.

This chart shows the closing price for HLTRF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in HLS Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/17/2023Stifel NicolausLower TargetC$26.00 ➝ C$18.00
3/17/2023Raymond JamesDowngradeOutperform ➝ Market Perform
11/11/2022Stifel NicolausLower TargetC$32.00 ➝ C$26.00
8/25/2022Raymond JamesLower TargetC$28.00 ➝ C$24.00
8/12/2022Stifel NicolausLower TargetC$36.00 ➝ C$32.00
5/6/2022Canaccord Genuity GroupLower TargetBuy ➝ BuyC$27.00 ➝ C$26.25
5/3/2022Raymond JamesBoost TargetC$26.00 ➝ C$28.00
4/28/2022Canaccord Genuity GroupLower TargetBuy ➝ BuyC$30.50 ➝ C$27.00
4/27/2022Clarus SecuritiesLower TargetC$33.00 ➝ C$26.50
3/18/2022Canaccord Genuity GroupLower TargetBuy ➝ BuyC$30.75 ➝ C$30.50
8/17/2021Raymond JamesUpgradeMarket Perform ➝ Outperform
8/16/2021Clarus SecuritiesBoost TargetBuyC$32.50 ➝ C$33.00
8/6/2021Raymond JamesDowngradeOutperform ➝ Market Perform
3/24/2021Raymond JamesBoost TargetOutperform$27.00 ➝ $28.00
1/21/2021Raymond JamesInitiated CoverageOutperform
10/1/2020Clarus SecuritiesBoost TargetBuy$31.00 ➝ $33.25
7/21/2020Stifel NicolausBoost TargetBuy$35.00 ➝ $36.00
(Data available from 3/30/2018 forward)

News Sentiment Rating

-0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
HLS Therapeutics logo
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
Read More

Today's Range

Now: $4.47
Low: $4.47
High: $4.47

50 Day Range

MA: $6.35
Low: $4.46
High: $7.67

52 Week Range

Now: $4.47
Low: $4.46
High: $12.01

Volume

N/A

Average Volume

7,920 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of HLS Therapeutics?

The following equities research analysts have issued research reports on HLS Therapeutics in the last year: Canaccord Genuity Group Inc., Clarus Securities, Raymond James, and Stifel Nicolaus.
View the latest analyst ratings for HLTRF.

What is the current price target for HLS Therapeutics?

4 Wall Street analysts have set twelve-month price targets for HLS Therapeutics in the last year. Their average twelve-month price target is $23.69, suggesting a possible upside of 429.9%. Clarus Securities has the highest price target set, predicting HLTRF will reach $26.50 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $18.00 for HLS Therapeutics in the next year.
View the latest price targets for HLTRF.

What is the current consensus analyst rating for HLS Therapeutics?

HLS Therapeutics currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HLTRF will outperform the market and that investors should add to their positions of HLS Therapeutics.
View the latest ratings for HLTRF.

What other companies compete with HLS Therapeutics?

Other companies that are similar to HLS Therapeutics include 1933 Industries, 4Front Ventures, AB Science, Abacus Health Products and Acreage. Learn More about companies similar to HLS Therapeutics.